BICO Group (CLLKF) Fair Value & Analysis
Healthcare · US · Market cap $124M
BICO Group
CLLKF · US
Fair value as of: Jul 15, 2026
From 7 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $11.64 to $3.24 (−72.2%) since Jun 24, 2026. Share price −13.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.52 – $3.95 · fair‑value band $2.71 – $3.88 · the $1.52 price screens below the $3.24 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BICO Group (CLLKF) currently trades at $1.52, while our model-based Fair Value estimate is $3.24 — implying the stock looks roughly 112.9% undervalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, BICO Group generated revenue of $1.8B at a net margin of -66.1%. Revenue declined 1.4% year over year. It earns a return on equity of -69.3%. Net debt stands at $222M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $2.71 (bear case) to $3.88 (bull case); at $1.52, the current price sits below that range. The share trades about 61% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at 113%, CLLKF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BICO Group reported revenue of $1.5B in FY2025 versus $1.3B in FY2021, a compound +4.4%/yr. Reported net income was −$1.1B in FY2025.
Is CLLKF fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €78.04 | €61.19 | -22% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BICO Group (CLLKF) undervalued?
What is the fair value of CLLKF?
What is the quality score of CLLKF?
What is the revenue of BICO Group (CLLKF)?
What is the net profit margin of CLLKF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BICO Group analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.